Drug intelligence / Profile preview

TCN-202

Development stage: Phase 1
Lead developer: Theraclone Sciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous

Overview

TCN-202 is a recombinant, fully human monoclonal antibody developed for the treatment and prevention of cytomegalovirus (CMV) infections. It was discovered using Theraclone Sciences’ I-STAR platform, which identifies natural human antibodies with broad biologic activity. TCN-202 targets a universal protein within CMV variants, aiming to provide broad protection against the virus and reduce the risk of drug resistance due to viral mutations. The drug has been investigated particularly for use in immunocompromised individuals and congenital CMV infection, where complications can be severe or life-threatening. It received orphan drug designation for congenital CMV infection but development has since been discontinued[4][5][6][7][8][10].

Other names: human anti-cytomegalovirus monoclonal antibody

Targets

gB (Human cytomegalovirus glycoprotein B)

Beyond the preview

Go deeper on TCN-202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TCN-202.

Explore the full profile